As we learn more about the biology of AML, it appears that 7+3 only rarely clears residual leukemic clones in patients with higher-risk disease. New therapies are needed that can target and eradicate resistant subclones early in the disease course.
Andrew M. Brunner, MD
Advertisement
Articles by Andrew M. Brunner, MD
Advertisement
Latest Updated Articles
COUNTERPOINT: Standard vs Investigational Agents as Upfront Treatment for High-Risk AMLPublished: March 15th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
2
H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice
3
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
4
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
5
